Skip to main content
SpringerLink
Log in

Medical Treatment of Hypertrophic Cardiomyopathy

  • Conference paper
Advances in Cardiomyopathies

Abstract

In 1907 Schmincke [93] was the first to describe diffuse “hyperplasia” of the heart muscle, involving predominantly the wall of the left ventricular outflow tract, in two female patients. In 1958 Teare [104] presented pathologic findings of asymmetrical hypertrophy of the heart in young adults, eight of whom died from sudden death, seven of them during physical activity. In 1964 Braunwald et al. [9] described the findings in 64 patients with hypertrophic cardiomyopathy (HCM), emphasizing angiographically determined normal or even supernormal left ventricular function and hemodynamically documented large variations of outflow tract gradient. Today, there seems to be no doubt that impaired diastolic function of the left ventricle is the predominant hemodynamic characteristic in HCM [106, 107].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Adelmann AG, Shah PM, Gramiak R, Wigle ED (1970) Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 32: 804–811

    Article  Google Scholar 

  2. Adelman AG, Wigle ED, Ranganathan R, Webb GD, Kidd BSC, Bigelow WG, Silver MD (1972) The clinical course of muscular subaortic stenosis. Ann Intern Med 77: 515–525

    PubMed  CAS  Google Scholar 

  3. Anderson DM, Raff GL, Ports TA, Brundage BH, Parmley WW, Chatterjee K (1984) Hypertrophic obstructive cardiomyopathy: effects of acute and chronic verapamil treat-ment on left ventricular systolic and diastolic function. Br Heart J 51: 523–529

    Article  PubMed  CAS  Google Scholar 

  4. Assmann H, Assmann I, Fiehring H, Dittrich P, Eger H (1975) Verlaufsbeobachtungen bei der idiopathischen hypertrophischen subaortalen Stenose unter Propranololbehandlung. Dtsch Gesundheitswes 30: 918–920

    Google Scholar 

  5. Betocchi S, Cannon RO, Watson RM, Bonow RO, Ostrow HG, Epstein SE, Rosing DR (1985) Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy. Circulation 72: 1001–1007

    Article  PubMed  CAS  Google Scholar 

  6. Bonow RO, Rosing DR, Bacharach SL, Green MV, Kent KM, Lipson LC, Maron BJ, Epstein SE (1981) Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 64: 787–796

    Article  PubMed  CAS  Google Scholar 

  7. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV (1985) Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 72: 853–864

    Article  PubMed  CAS  Google Scholar 

  8. Braunwald E, Ebert PA (1962) Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. Am J Cardiol 10: 489–491

    Article  PubMed  CAS  Google Scholar 

  9. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG (1964) Idiopathic hypertrophic subaortic stenosis: A description of the disease based upon an analysis of 64 patients. Circulation [Suppl 4] 30:IV 3–IV 213

    Google Scholar 

  10. Bryhn M, Eskilsson J (1987) Effects of verapamil on left ventricular diastolic function at rest and during isometric exercise in patients with hypertrophic cardiomyopathy. Clin Cardiol 10: 31–36

    Article  PubMed  CAS  Google Scholar 

  11. Cherian G, Brockington IF, Shah PM, Oakley CM, Goodwin JF (1966) Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy. Br Med J 1: 895–898

    Article  Google Scholar 

  12. Cohen LS, Braunwald E (1967) Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta adrenergic blockade. Circulation 35: 847–851

    PubMed  CAS  Google Scholar 

  13. Cranefield PF, Aronson RS, Wit AL (1974) Effect of verapamil on the normal action potential and on a calcium dependent slow response of canine Purkinje fibers. Circ Res 34: 204–213

    PubMed  CAS  Google Scholar 

  14. Cserhalmi L, Aßmann I, Glavanow M, Rev J, Kelecseneyi Z (1984) Langzeittherapie der hypertrophischen obstruktiven und nichtobstruktiven Kardiomyopathie mit Nifedipin im Vergleich zu Propranolol. Z Gesamte Inn Med 39: 330–335

    PubMed  CAS  Google Scholar 

  15. De la Calzada CS, Ziady GM, Hardarson T, Curiel R, Goodwin JF (1976) Effect of acute administration of propranolol on ventricular function in hypertrophic obstructive cardiomyopathy measured by non-invasive techniques. Br Heart J 38: 798–803

    Article  Google Scholar 

  16. El Gamal M, Schasfort GBA, Schrijvers LCM (1975) Relief of severe left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy treated with practolol. Br Heart J 37: 225–228

    Article  PubMed  CAS  Google Scholar 

  17. Enia F, Comparato C, DiFranca F, Ledda A, Mizio G (1987) Systolic anterior motion of the mitral valve in patients with hypertrophic cardiomyopathy: disappearance after treatment with amiodarone. Chest 91: 277–278

    Article  PubMed  CAS  Google Scholar 

  18. Epstein SE, Maron BJ (1980) Hypertrophic cardiomyopathy: an overview. Clin Invest Med 3: 185–193

    PubMed  CAS  Google Scholar 

  19. Epstein SE, Rosing DR (1981) Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 64: 437–441

    Article  PubMed  CAS  Google Scholar 

  20. Flamm MD, Harrison DC, Hancock EW (1968) Muscular subaortic stenosis: prevention of outflow obstruction with propranolol. Circulation 38: 846–858

    PubMed  CAS  Google Scholar 

  21. Frank MJ, Abdulla AM, Canedo MI, Saylors RE (1978) Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 42: 993–1001

    Article  PubMed  CAS  Google Scholar 

  22. Frank MJ, Abdulla AM, Watkins LO, Prisant L, Stefadouros MA (1983) Long-term medical management of hypertrophic cardiomyopathy: usefulness of propranolol. Eur Heart J [Suppl F] 4: 155–164

    Google Scholar 

  23. Frank MJ, Watkins LO, Abdulla AM (1985) Management with beta-adrenergic blocking drugs. In: Ten Cate FJ (ed) Hypertrophic cardiomyopathy: clinical recognition and management. Dekker, New York, pp 155–172

    Google Scholar 

  24. Goodwin JF (1970) Congestive and hypertrophic cardiomyopathies. A decade of study. Lancet 1: 731–739

    Article  Google Scholar 

  25. Goodwin JF (1973) Treatment of cardiomyopathies. Am J Cardiol 32: 341–351

    Article  PubMed  CAS  Google Scholar 

  26. Goodwin JF, Shah M, Oakley CM, Cohen J, Yipintsoi T, Pocock W (1964) The clinical pharmacology of hypertrophic obstructive cardiomyopathy. In: Wolstenholme GEW, O’Connor M (eds) Cardiomyopathies. Churchill, London, pp 189–213

    Google Scholar 

  27. Gorlin R, Cohen LS, Elliott WC, Klein MD, Lane FJ (1964) Haemodynamics of muscular subaortic stenosis (obstructive cardiomyopathy). In: Wolstenholme GEW, O’Connor M (eds) Cardiomyopathies. Churchill, London, pp 76–99

    Chapter  Google Scholar 

  28. Gotsman MS, Lewis BS (1974) Left ventricular volumes and compliance in hypertrophic cardiomyopathy. Chest 66: 498–505

    Article  PubMed  CAS  Google Scholar 

  29. Haberer T, Hess OM, Jenni R, Krayenbühl HP (1983) Hypertrophe obstruktive Kardiomyopathie: Spontanverlauf im Vergleich zur Langzeittherapie mit Propranolol und Verapamil. Z Kardio 72: 487–493

    CAS  Google Scholar 

  30. Hanrath P, Mathey DG, Kremer P, Sonntag F, Bleifeld W (1980) Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol 45: 1258–1264

    Article  PubMed  CAS  Google Scholar 

  31. Hanrath P, Schlüter M, Sonntag F, Diemert J, Bleifeld W (1983) Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathy. Am J Cardiol 52: 544–548

    Article  PubMed  CAS  Google Scholar 

  32. Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr (1964) Effects of beta adrenergic blockade on the circulation, with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 29: 84–98

    PubMed  CAS  Google Scholar 

  33. Hess OM, Grimm J, Krayenbühl HP (1983) Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness. Eur Heart J [Suppl F] 4: 47–56

    Google Scholar 

  34. Hopf R, Kaltenbach M (1977) Röntgenologische Herzvolumenbestimmung: Beschreibung einer neuen Methode mit Durchführung im Sitzen. Fortschr Geb Röntgenstr 127: 167–169

    Article  CAS  Google Scholar 

  35. Hopf R, Kaltenbach M (1982) Verapamil treatment of hypertrophic cardiomyopathy. In: Kaltenbach M, Epstein SE (eds) Hypertrophic cardiomyopathy. The therapeutic role of calcium antagonists. Springer, Berlin Heidelberg New York, pp 163–178

    Google Scholar 

  36. Hopf R, Kaltenbach M (1982) Die hypertrophische Kardiomyopathie: Möglichkeiten der kalziumantagonistischen Behandlung. Thieme, Stuttgart, pp 129–137

    Google Scholar 

  37. Hopf R, Kaltenbach M (1984) Einfluß hoher Dosen von Verapamil auf die linksventrikuläre Hämodynamik. In: Gross F (ed) Die Bedeutung der Kalzium-Antagonisten für die Hochdrucktheraphie. MMW Medizin, München, pp 41–57

    Google Scholar 

  38. Hopf R, Kaltenbach M (1987) 10-year results and survival of patients with hypertrophic cardiomyopathy treated with calcium antagonists. Z Kardiol [Suppl 3] 76: 137–144

    Google Scholar 

  39. Hopf R, Kaltenbach M (1988) Medical treatment of hypertrophic cardiomyopathy: Influence on outflow obstruction and filling pressure. In: Toshima H, Maron BJ (eds) Cardiomyopathy update 2: Hypertrophic cardiomyopathy. University of Tokyo Press, Tokyo, pp 189–205

    Google Scholar 

  40. Hopf R, Keller M, Kaltenbach M (1976) Die Behandlung der hypertrophen obstruktiven Kardiomyopathie mit Verapamil. Verh Dtsch Ges Inn Med 82 (2): 1054–1057

    PubMed  Google Scholar 

  41. Hopf R, Kaltenbach M, Kober G (1981) Verapamil in the treatment of hypertrophic obstructive cardiomyopathy. In: Zanchetti A, Krikler DH (eds) Calcium antagonism in cardiovascular therapy - Experience with verapamil. Excerpta Medica, Amsterdam, pp 353–362

    Google Scholar 

  42. Hopf R, Kober G, Kaltenbach M (1983) Die Behandlung der hypertrophen Kardio-myopathie mit Kalziumantagonisten. In: Olsen EG, Schrey A (eds) Expertengespräche Venedig 1981 - Medikamentöse Behandlung ausgewählter kardiovaskulärer Krankheiten. Klett, Stuttgart, pp 226–244

    Google Scholar 

  43. Hopf R, Richter H, Kaltenbach M, Maul FD, Standke R, Hör G (1985) Radionuklid- ventrikulographie nach akuter und chronischer Verapamil-Medikation bei Patienten mit hypertropher Kardiomyopathie. In: Hör G, Kaltenbach M, Maul FD, Pabst HW (eds) Interventionelle Nuklearkardiologie. Kern und Birner, Frankfurt, pp 368–377

    Google Scholar 

  44. Hopf R, Rodrian S, Kaltenbach M (1986) Behandlung der hypertrophen Kardiomyopathie mit Kalziumantagonisten: Eine Zehnjahresbilanz. Therapiewoche 36: 1433–1454

    Google Scholar 

  45. Hopf R, Thomas J, Klepzig H, Kaltenbach M (1987) Behandlung der hypertrophischen Kardiomyopathie mit Nifedipin und Propranolol in Kombination. Z Kardiol 76: 469–478

    PubMed  CAS  Google Scholar 

  46. Kaltenbach M, Hopf R (1984) Use of calcium-channel blockers in the treatment of hypertrophic cardiomyopathy. Pract Cardiol 10: 197–215

    Google Scholar 

  47. Kaltenbach M, Hopf R (1984) Long-term treatment of hypertrophic myocardiopathy with calcium antagonists. In: Althaus U, Burckhardt D, Vogt E (eds) Calcium-Antagonismus. International symposium on calcium-antagonism. Uni Versi Med, Frankfurt, pp 259–271

    Google Scholar 

  48. Kaltenbach M, Hopf R (1985) Treatment of hypertrophic cardiomyopathy: Relation to pathological mechanism. J Mol Cell Cardiol [Suppl 2] 17: 59–68

    Article  Google Scholar 

  49. Kaltenbach M, Hopf R, Keller M (1976) Calciumantagonistische Therapie bei hypertroph obstructiver Kardiomyopathie. Dtsch Med Wochenschr 101: 1907–1911

    Article  PubMed  CAS  Google Scholar 

  50. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y (1979) Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 42: 35–42

    Article  PubMed  CAS  Google Scholar 

  51. Kober G, Hopf R, Biamino G, Bubenheimer P, Förster K, Kuck KH, Hanrath P et al (1987) Long-term treatment of hypertrophic cardiomyopathy with verapamil or propranolol in matched pairs of patients. Results of a multicenter study. Z Kardiol [Suppl 3] 76: 113–118

    Google Scholar 

  52. Krayenbühl HP, Hirzel HO, Hess OM, Senn M (1983) Behandlung der hypertrophen Kardiomyopathie mit Kalzium-Antagonisten. In: Fleckenstein A, Hashimoto K, Herrmann M, Schwartz A, Seipel L (eds) New calcium antagonists: recent developements and prospects. Fischer, Stuttgart, pp 199–210

    Google Scholar 

  53. Kuhn H, Loogen F (1978) Die Anwendung von Beta-Rezeptorenblockern bei hyper-trophischer obstruktiver Kardiomyopathie ( HOCM ). Internist (Berlin) 19: 527–531

    Google Scholar 

  54. Kuhn H, Thelen U, Leuner C, Köhler E, Bluschke V (1980) Langzeitbehandlung der hypertrophischen nicht obstruktiven Kardiomyopathie ( HNCM) mit Verapamil. Z Kardiol 69: 669–675

    PubMed  CAS  Google Scholar 

  55. Landmark K, Sire S, Thanlow E, Amlie JP, Nitter-Hange S (1982) Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy. Br Heart J 48: 19–26

    Article  PubMed  CAS  Google Scholar 

  56. Leon MB, Rosing DR, Maron BJ, Bonow RO, Lesko LL, Epstein SE (1984) Amiodarone in patients with hypertrophic cardiomyopathy and refractory cardiac symptoms: an alternative to current medical therapy. Circulation [Suppl 2] 70: 11–18

    Google Scholar 

  57. Leon MB, Tracy CM, Winkler J, Bergamo C, Bonow RO, Epstein SE (1987) Amiodarone does not prevent, and may increase, sudden death in patients with hypertrophic cardiomyopathy (Abstr). Circulation [Suppl 4] 76: 248

    Google Scholar 

  58. Linden RJ (1964) Related physiology of cardiac contraction. In: Wolstenholme GEW, O’Connor M (eds) Cardiomyopathies. Churchill, London, pp 100–131

    Chapter  Google Scholar 

  59. Loogen F, Kuhn H, Krelhaus W (1978) Natural history of hypertrophic cardiomyopathy and the effect of therapy. In: Kaltenbach M, Loogen F, Olssen EG (ed) Cardiomyopathy and myocardial biopsy. Springer, Berlin Heidelberg New York, pp 286–299

    Chapter  Google Scholar 

  60. Loogen F, Kuhn H, Gietzen F, Lösse B, Schulte HD, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. Eur Heart J [Suppl F] 4: 145–153

    Google Scholar 

  61. Lorell BH, Paulus WJ, Grossman W, Wynne J, Cohn PF, Braunwald E (1980) Improved diastolic function and systolic performance in hypertrophic cardiomyopathy after nifedipine. N Engl J Med 303: 801–803

    Article  PubMed  CAS  Google Scholar 

  62. Lorell BH, Paulus WJ, Grossman W, Wynne J, Cohn PF (1982) Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation 65: 499–507

    Article  PubMed  CAS  Google Scholar 

  63. Lösse B, Kuhn H, Loogen F, Schulte HD (1983) Exercise performance in hypertrophic cardiomyopathies. Eur Heart J [Suppl F] 4: 197–208

    Google Scholar 

  64. Maron BJ, Savage DD, Wolfson JK, Epstein SE (1981) The prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy. Am J Cardiol 48: 252–257

    Article  PubMed  CAS  Google Scholar 

  65. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 316:780-789, 844–852

    Article  PubMed  CAS  Google Scholar 

  66. Masini V, Ceci V, Malinconico U, Milazzotto F (1981) Therapeutic evaluation of pindolol and verapamil in hypertrophic obstructive cardiomyopathy. G Ital Cardiol 11: 1729–1737

    PubMed  CAS  Google Scholar 

  67. McKenna WJ (1983) Arrhythmia and prognosis in hypertrophic cardiomyopathy. Eur Heart J [Suppl F] 4: 225–234

    Google Scholar 

  68. McKenna WJ, Kleinebenne A (1985) Arrhythmien bei hypertrophischer Kardiomyopathie: Bedeutung und therapeutische Konsequenzen. Herz 10: 91–101

    PubMed  CAS  Google Scholar 

  69. McKenna WJ, Chetty S, Oakley CM, Goodwin JF (1980) Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 45: 1–5

    Article  PubMed  CAS  Google Scholar 

  70. McKenna WJ, England D, Oakley C, Goodwin J (1980) Detection of arrhythmia in hypertrophic cardiomyopathy: prospective study (Abstr). Circulation [Suppl 3] 62: 187

    Google Scholar 

  71. McKenna WJ, England D, Oakley C, Goodwin JF (1981) Detection of arrhythmia in hypertrophic cardiomyopathy. I. Influence on prognosis. Br Heart J 46: 168–172

    Article  PubMed  CAS  Google Scholar 

  72. McKenna WJ, Harris L, Perez G, Krikler DM, Oakley C, Goodwin JF (1981) Arrhythmia in hypertrophic cardiomyopathy. II. Comparison of amiodarone and verapamil in treatment. Br Heart J 46: 173–178

    Article  PubMed  CAS  Google Scholar 

  73. Deleted

    Google Scholar 

  74. McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, Oakley CM, Goodwin JF (1984) Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 54: 802–810

    Article  PubMed  CAS  Google Scholar 

  75. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF (1985) Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 53: 412–416

    Article  PubMed  CAS  Google Scholar 

  76. McKenna WJ, Harris L, Mulrow JP, Rowland E, Holt DW (1986) Amiodarone dose titration: a method to minimise side effects during long-term therapy. Br J Clin Proctol [Suppl 44] 40: 121–127

    Google Scholar 

  77. Mushoff K, Reindell H (1956) Zur Röntgenuntersuchung des Herzens in horizontaler und vertikaler Körperstellung. I Mitteilung: Der Einfluß der Körperstellung auf das Herzvolumen. Dtsch Med Wochenschr 81: 1001–1008

    Article  Google Scholar 

  78. Mushoff K, Reindell H (1957) Zur Röntgenuntersuchung des Herzens in horizontaler und vertikaler Körperstellung: II Mitteilung: Der Einfluß der Körperstellung auf die Herzform. Dtsch Med Wochenschr 82: 1075–1080

    Article  Google Scholar 

  79. Nagao M, Omote S, Takizawa A, Yasue H (1983) Effect of diltiazem on left ventricular isovolumic relaxation time in patients with hypertrophic cardiomyopathy. Jpn Circ J 47: 58

    Article  Google Scholar 

  80. Oakley CM (1973) Beta-adrenergic blocking agents in hypertrophic cardiomyopathy (HOCM). Singapore Med J 14: 408–409

    PubMed  CAS  Google Scholar 

  81. Olbrich HG, Borgers M, Thone F, Frotscher M, Mutschier E, Schneider M, Kober G, Kaltenbach M (1988) Ultrastructural localization of calcium in the myocardium of cardiomyopathic Syrian Hamsters. J Mol Cell Cardiol 20: 753–762

    Article  PubMed  CAS  Google Scholar 

  82. Paulus WJ, Lorell BH, Craig WE, Wynne J, Murgo JP, Grossman W (1983) Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: altered left ventricular loading or improved muscle inac- tivation? J Am Coll Cardiol 2: 879–886

    Article  PubMed  CAS  Google Scholar 

  83. Paulus WJ, Nellens P, Heyndrickx GR, Andries E (1986) Effects of long-term treatment with amiodarone on exercise hemodynamics and left ventricular relaxation in patients with hypertrophic cardiomyopathy. Circulation 74: 544–554

    Article  PubMed  CAS  Google Scholar 

  84. Pollik C (1982) Muscular aortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 307: 997–999

    Article  Google Scholar 

  85. Pollik C (1988) Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. Am J Cardiol 62: 1252–1255

    Article  Google Scholar 

  86. Pollik C, Kimball B, Henderson M, Wigle ED (1988) Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 62: 1248–1251

    Article  Google Scholar 

  87. Rosing DR, Kent KM, Borer DJ, Seides SF, Maron BJ, Epstein SE (1979) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 60: 1201–1207

    PubMed  CAS  Google Scholar 

  88. Rosing DR, Kent KM, Maron BJ, Epstein SE (1979) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 60: 1208–1213

    PubMed  CAS  Google Scholar 

  89. Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, Lipson LC, Epstein SE (1981) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. III. Effects of long-term administration. Am J Cardiol 48: 545–553

    Article  PubMed  CAS  Google Scholar 

  90. Rosing DR, Idänpään-Heikkilä U, Maron BJ, Bonow RO, Epstein SE (1985) Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol [Suppl 1] 55:185 B–195 B

    Article  Google Scholar 

  91. Rothlin ME, Gobet D, Haberer T, Krayenbühl HP, Turina M, Senning A (1983) Surgical treatment versus medical treatment in hypertrophic obstructive cardiomyopathy. Eur Heart J [Suppl F] 4: 215–223

    Google Scholar 

  92. Schanzenbächer P, Schick KD, Kochsiek K (1982) Nifedipin bei hypertrophisch obstruktiver Kardiomyopathie. Dtsch Med Wochenschr 107: 1842–1846

    Article  PubMed  Google Scholar 

  93. Schmincke A (1907) Über linksseitige muskuläre Conusstenosen. Dtsch Med Wochenschr 33: 2082–2083

    Article  Google Scholar 

  94. Senn M, Hess OM, Krayenbühl HP (1982) Nifedipin in der Behandlung der hypertrophen, nicht obstruktiven Kardiomyopathie. Schweiz Med Wochenschr 112: 1312–1317

    PubMed  CAS  Google Scholar 

  95. Shah PM, Adelman AG, Wigle Ed, Gobel FL, Burchell HB, Hardarson T, Curiel R et al (1973) The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. A multicenter study. Circ Res [Suppl 2] 34: 179–195

    Google Scholar 

  96. Sherrid M, Delia E, Dwyer E (1988) Oral disopyramide therapy for obstructive hyper- tophic cardiomyopathy. Am J Cardiol 62: 1085–1088

    Article  PubMed  CAS  Google Scholar 

  97. Sonntag F, Hanrath P, Saal M, Diemert J, Mathey D, Kupper W, Bleifeld W (1980) Untersuchungen zur Frage der Häufigkeit und Vorhersehbarkeit von ventrikulären Herzrhythmusstörungen bei Patienten mit hypertropher Kardiomyopathie. Herz Kreislauf 12: 481–189

    Google Scholar 

  98. Sowton E (1976) Betarezeptorenblocker bei hypertropher Kardiomyopathie. In: Schweizer W (ed) Die Betablocker-Gegenwart und Zukunft. Huber, Bern, pp 239–258

    Google Scholar 

  99. Spicer RL, Rocchini AP, Crowley DC, Vasiliades J, Rosenthal A (1983) Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. Circulation 67: 413–420

    Article  PubMed  CAS  Google Scholar 

  100. Stenson RE, Flamm MD Jr, Harrison DC, Hancock EW (1973) Hypertrophic subaortic stenosis: clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol 31: 763–773

    Article  PubMed  CAS  Google Scholar 

  101. Sugrue DD, Dickie S, Myers MJ, Lavender JP, McKenna WJ (1984) Effect of amiodar- one on left ventricular ejection and filling in hypertrophic cardiomyopathy as assessed by radionuclide angiography. Am J Cardiol 54: 1054–1058

    Article  PubMed  CAS  Google Scholar 

  102. Suwa M, Hirota Y, Kawamura K (1984) Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: an echocardiographic study. Am J Cardiol 54: 1047–1053

    Article  PubMed  CAS  Google Scholar 

  103. Swanton RH, Brooksby I AB, Jenkins BS, Webb-Peploe MM (1977) Hemodynamic studies of beta-blockade in hypertrophic obstructive cardiomyopathy. Eur J Cardiol 5 (4): 327–341

    PubMed  CAS  Google Scholar 

  104. Teare D (1958) Asymmetrical hypertrophy of the heart in young adults. Br Heart J 20: 1–8

    Article  PubMed  CAS  Google Scholar 

  105. Wagner JA, Sax FL, Weisman HF, Porterfield J, Mcintosh C, Weisfeld ML, Snyder SH, Epstein SE (1989) Calcium-antagonist receptors in the atrial tissue of patients with hypertrophic cardiomyopathy. N Engl J Med 320: 755–761

    Article  PubMed  CAS  Google Scholar 

  106. Wigle ED, Wilansky S (1987) Diastolic dysfunction in hypertrophic cardiomyopathy. Heart Failure 2: 82–93

    Google Scholar 

  107. Wigle ED, Heimbecker RO, Gunton RW (1962) Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. Circulation 26: 325–340

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. Hopf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kaltenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Istituto Fisiologia Clinica CNR, Dipartimento di Cardiologia A. De Gasperis, Ospedale Niguarda, Ca’ Granda, Piazza Ospedale Maggiore 3, 20612, Milan, Italy

    G. Baroldi M.D.

  2. Dipartimento di Cardiologia, Ospedale Maggiore, Piazza Ospedale 1, 34129, Trieste, Italy

    F. Camerini M.D.

  3. 2 Pine Grove, Lake Road, SW19 7HE, Wimbledon, London, UK

    J. F. Goodwin M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hopf, R., Kaltenbach, M. (1990). Medical Treatment of Hypertrophic Cardiomyopathy. In: Baroldi, G., Camerini, F., Goodwin, J.F. (eds) Advances in Cardiomyopathies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83760-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83760-9_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-83762-3

  • Online ISBN: 978-3-642-83760-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation